查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1482443

傳染病體外診斷市場：依地區：全球產業分析、規模、佔有率、成長、趨勢、預測，2024-2031

Infectious Disease In-vitro Diagnostics Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 250 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

持久性市場研究對全球傳染病體外診斷 (IVD) 市場進行了廣泛分析，深入瞭解市場趨勢、成長動力、課題和新興趨勢。該報告提供了詳細的數據和統計數據以引導市場格局，並為利害關係人提供全面的指南。

在全球傳染病疫情數量增加的背景下，預計2024年至2031年全球傳染病體外診斷市場將大幅成長。該市場預計將從 2024 年的 668 億美元成長到 2031 年的 902 億美元，期間複合年增長率為 4.4%。

重要見解

  • 預計市場價值（2024年）：668億美元
  • 預計市值（2031年）902億美元
  • 全球市場成長率（2024-2031年複合年增長率）：4.4%

傳染病體外診斷市場 - 報告範圍

體外診斷在傳染病的檢測和管理中發揮重要作用，為有效的患者護理提供快速、準確的結果。該市場包括廣泛的診斷測試，例如分子測定、免疫測定和旨在檢測各種傳染源（例如細菌、病毒和寄生蟲）的護理點測試。

在全球化、都市化和抗菌素抗藥性等因素的推動下，傳染病發生率不斷上升，推動了對診斷測試的需求。此外，持續的 COVID-19 大流行凸顯了強大的診斷基礎設施和檢測能力對於限制疾病傳播和管理公共衛生危機的重要性。

市場成長動力：

有幾個因素促進了傳染病體外診斷市場的成長，包括愛滋病毒/愛滋病、結核病、瘧疾和肝炎等傳染病等傳染病率的上升。此外，新傳染源的出現和現有病原體的重新出現對公共衛生提出了重大課題，需要增強診斷能力。

分子診斷、新一代定序和快速護理點檢測等診斷技術的進步使得更快、更準確地檢測傳染性病原體成為可能。此外，醫療保健支出的增加、政府控制傳染病的努力以及人們對早期診斷重要性的認識不斷提高，都進一步推動了市場的成長。

市場限制因素：

儘管成長前景樂觀，傳染病體外診斷市場仍面臨一定的課題，包括監管障礙、報銷問題和供應鏈中斷。對診斷測試批准和報銷限制的嚴格監管要求可能會抑制製造商，特別是中小型企業進入市場。

此外，實施診斷測試基礎設施的複雜性和成本為市場擴張帶來了課題，特別是在資源有限的環境中。此外，測試表現的變化以及假陽性和假陰性的可能性可能會影響診斷準確性和患者結果，從而引起醫療保健提供者和患者的擔憂。

市場機會：

傳染病體外診斷市場提供了大量的創新和擴張機會，特別是在新型診斷技術和測試平台的開發方面。分子診斷學的進步，包括核酸擴增測試和多重檢測，正在提高傳染病檢測的敏感度、特異性和周轉時間。

此外，將人工智慧和機器學習演算法整合到診斷平台中可以增強數據分析和解釋，從而獲得更準確和可操作的診斷見解。此外，更多地採用現場檢測和分散診斷解決方案將能夠及時診斷和治療，特別是在服務不足和偏遠地區。

本報告解決的關鍵問題

  • 2024年至2031年傳染病體外診斷市場的預期CAGR值為何？
  • 推動傳染病體外診斷市場成長的關鍵因素是什麼？
  • 哪個地區在傳染病體外診斷市場中佔據最大的市場佔有率？
  • 全球傳染病體外診斷市場的主要參與者有哪些？
  • 主要參與者正在採取哪些策略來維持傳染病體外診斷市場的成長？

目錄

第一章執行摘要

第二章市場概況

  • 市場範圍/分類
  • 市場定義/範圍/限制

第三章市場背景

  • 市場動態
  • 情景預測
  • 機會圖分析
  • 產品生命週期分析
  • 投資可行性矩陣
  • PESTLE 與 Porter 分析
  • 監管狀況
  • 區域母公司市場展望

第四章 全球傳染病體外診斷市場分析

  • 過去的市場規模（金額）分析，2019-2023
  • 目前和未來市場規模（金額）預測，2024-2031

第 5 章：依產品類型劃分的全球傳染病體外診斷市場分析

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023
  • 當前和未來市場規模（金額）分析和預測，2024-2031
    • 機器
    • 試劑
    • 服務
  • 2019-2023年年成長趨勢分析
  • 2024-2031年絕對回報機會分析

第六章：全球傳染病體外診斷市場技術分析

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023
  • 當前和未來市場規模（金額）分析和預測，2024-2031
    • 免疫測定法
    • 分子診斷
    • 微生物學
    • 其他技術
  • 2019-2023年年成長趨勢分析
  • 絕對回報機會分析，2024-2031

第七章依應用：全球傳染病體外診斷市場分析

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023
  • 當前和未來市場規模（金額）分析和預測，2024-2031
    • 抗甲氧西林金黃色葡萄球菌
    • 鏈球菌
    • 艱難梭菌
    • 呼吸道病毒
    • 結核病和抗藥性結核病
    • 淋病
    • HPV病毒
    • 愛滋病
    • C型肝炎
    • B型肝炎
    • COVID-19
    • 其他應用
  • 2019-2023年年成長趨勢分析
  • 2024-2031年絕對回報機會分析

第 8 章：依最終用途劃分的全球傳染病體外診斷市場分析

  • 簡介/主要發現
  • 過去的市場規模（金額）分析，2019-2023
  • 當前和未來市場規模（金額）分析和預測，2024-2031
    • 注意事項
    • 中央研究所
    • 其他用途
  • 2019-2023年年成長趨勢分析
  • 2024-2031年絕對回報機會分析

第九章依地區劃分：全球傳染病體外診斷市場分析

  • 介紹
  • 過去的市場規模（金額）分析，2019-2023
  • 當前市場規模（金額）分析與預測，2024-2031
    • 北美
    • 拉丁美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲
  • 區域市場吸引力分析

第十章 北美傳染病體外診斷市場分析（依國家）

第十一章 拉丁美洲傳染病體外診斷市場分析（依國家）

第十二章歐洲傳染病體外診斷市場分析（依國家）

第十三章亞太傳染病體外診斷市場分析（依國家）

第十四章中東和非洲傳染病體外診斷市場分析（依國家）

第十五章 主要國家傳染病體外診斷市場分析

  • 美國
  • 加拿大
  • 巴西
  • 墨西哥
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳大利亞
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合酋長國
  • 以色列

第16章市場結構分析

  • 比賽儀表板
  • 競爭標桿
  • 主要參與者的市場佔有率分析

第 17 章 競爭分析

  • 衝突詳情
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Abbott
    • Quidel Corporation
    • OraSure Technologies, Inc
    • Hologic Inc.
    • Cepheid
    • Qiagen
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.

第 18 章使用的假設和首字母縮略詞

第19章研究方法論

簡介目錄
Product Code: PMRREP33205

Persistence Market Research presents an extensive analysis of the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing insights into market dynamics, growth drivers, challenges, and emerging trends. This report serves as a comprehensive guide for stakeholders, offering detailed data and statistics for navigating the market landscape.

The global infectious disease in-vitro diagnostics market is poised for significant growth between 2024 and 2031, driven by the increasing prevalence of infectious diseases worldwide. With a projected CAGR of 4.4% during this period, the market is estimated to expand from USD 66.8 billion in 2024 to USD 90.2 billion by 2031.

Key Insights:

  • Estimated Market Value (2024): USD 66.8 Billion
  • Projected Market Value (2031): USD 90.2 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.4%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

In-vitro diagnostics play a crucial role in the detection and management of infectious diseases, providing rapid and accurate results for effective patient care. The market encompasses a wide range of diagnostic tests, including molecular assays, immunoassays, and point-of-care tests, designed to detect various infectious agents such as bacteria, viruses, and parasites.

The increasing incidence of infectious diseases, fueled by factors such as globalization, urbanization, and antimicrobial resistance, drives the demand for diagnostic testing. Furthermore, the ongoing COVID-19 pandemic has underscored the importance of robust diagnostic infrastructure and testing capabilities to control disease spread and manage public health crises.

Market Growth Drivers:

Several factors contribute to the growth of the infectious disease IVD market, including the rising incidence of infectious diseases such as HIV/AIDS, tuberculosis, malaria, and hepatitis. Additionally, the emergence of new infectious agents and the re-emergence of existing pathogens pose significant public health challenges, necessitating enhanced diagnostic capabilities.

Advancements in diagnostic technologies, including molecular diagnostics, next-generation sequencing, and rapid point-of-care testing, enable faster and more accurate detection of infectious agents. Moreover, increased healthcare spending, government initiatives to combat infectious diseases, and growing awareness about the importance of early diagnosis further drive market growth.

Market Restraints:

Despite its positive growth outlook, the infectious disease IVD market faces certain challenges, including regulatory hurdles, reimbursement issues, and supply chain disruptions. Stringent regulatory requirements for diagnostic test approval and reimbursement limitations can hinder market access for manufacturers, particularly small and medium-sized enterprises.

Furthermore, the complexity and cost of implementing diagnostic testing infrastructure, especially in resource-limited settings, pose challenges to market expansion. Additionally, the variability in test performance and the potential for false-positive or false-negative results can impact diagnostic accuracy and patient outcomes, leading to concerns among healthcare providers and patients.

Market Opportunities:

The infectious disease IVD market presents numerous opportunities for innovation and expansion, particularly in the development of novel diagnostic technologies and test platforms. Advances in molecular diagnostics, including nucleic acid amplification tests and multiplex assays, offer improved sensitivity, specificity, and turnaround time for infectious disease detection.

Furthermore, the integration of artificial intelligence and machine learning algorithms into diagnostic platforms enhances data analysis and interpretation, leading to more accurate and actionable diagnostic insights. Moreover, the increasing adoption of point-of-care testing and decentralized diagnostic solutions enables timely diagnosis and treatment, particularly in underserved and remote areas.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Infectious Disease IVD Market from 2024 to 2031?
  • What are the Key Factors Driving the Growth of the Infectious Disease IVD Market?
  • Which Region Holds the Largest Market Share in the Infectious Disease IVD Market?
  • Who are the Key Players in the Global Infectious Disease IVD Market?
  • What Strategies are Adopted by Leading Companies to Sustain Growth in the Infectious Disease IVD Market?

Competitive Landscape and Business Strategies:

Leading companies in the infectious disease IVD market include Roche Diagnostics, Abbott Laboratories, and bioMerieux SA. These companies focus on product innovation, research and development, and strategic partnerships to maintain their competitive edge.

Strategies such as expanding product portfolios, geographic expansion, and mergers and acquisitions are employed to enhance market presence and gain a competitive advantage. Furthermore, collaborations with healthcare organizations, government agencies, and research institutions facilitate the development and commercialization of novel diagnostic solutions.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • bioMerieux SA
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • QIAGEN N.V.
  • Cepheid Inc.

Infectious Disease IVD Market Segmentation:

By Product Type:

  • Instruments
  • Reagents
  • Services

By Technology:

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Other Technologies

By Application:

  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Other Applications

By End-use:

  • Point of care
  • Central Laboratories
  • Other End-uses

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Technology Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Background

  • 3.1. Market Dynamics
    • 3.1.1. Drivers
    • 3.1.2. Restraints
    • 3.1.3. Opportunity
    • 3.1.4. Trends
  • 3.2. Scenario Forecast
    • 3.2.1. Demand in Optimistic Scenario
    • 3.2.2. Demand in Likely Scenario
    • 3.2.3. Demand in Conservative Scenario
  • 3.3. Opportunity Map Analysis
  • 3.4. Product Life Cycle Analysis
  • 3.5. Investment Feasibility Matrix
  • 3.6. PESTLE and Porter's Analysis
  • 3.7. Regulatory Landscape
    • 3.7.1. By Key Regions
    • 3.7.2. By Key Countries
  • 3.8. Regional Parent Market Outlook

4. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast, 2024-2031

  • 4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
  • 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2031
    • 4.2.1. Y-o-Y Growth Trend Analysis
    • 4.2.2. Absolute $ Opportunity Analysis

5. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Product Type

  • 5.1. Introduction / Key Findings
  • 5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2019-2023
  • 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
    • 5.3.1. Instruments
    • 5.3.2. Reagents
    • 5.3.3. Services
  • 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019-2023
  • 5.5. Absolute $ Opportunity Analysis By Product Type, 2024-2031

6. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Technology

  • 6.1. Introduction / Key Findings
  • 6.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2019-2023
  • 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2024-2031
    • 6.3.1. Immunoassay
    • 6.3.2. Molecular Diagnostics
    • 6.3.3. Microbiology
    • 6.3.4. Other Technologies
  • 6.4. Y-o-Y Growth Trend Analysis By Technology, 2019-2023
  • 6.5. Absolute $ Opportunity Analysis By Technology, 2024-2031

7. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Application

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2019-2023
  • 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2024-2031
    • 7.3.1. MRSA
    • 7.3.2. Streptococcus
    • 7.3.3. Clostridium Difficile
    • 7.3.4. Respiratory Virus
    • 7.3.5. TB and Drug-resistant TB
    • 7.3.6. Gonorrhea
    • 7.3.7. HPV
    • 7.3.8. HIV
    • 7.3.9. Hepatitis C
    • 7.3.10. Hepatitis B
    • 7.3.11. COVID-19
    • 7.3.12. Other Applications
  • 7.4. Y-o-Y Growth Trend Analysis By Application, 2019-2023
  • 7.5. Absolute $ Opportunity Analysis By Application, 2024-2031

8. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By End-use

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2019-2023
  • 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2024-2031
    • 8.3.1. Point of care
    • 8.3.2. Central Laboratories
    • 8.3.3. Other End-uses
  • 8.4. Y-o-Y Growth Trend Analysis By End-use, 2019-2023
  • 8.5. Absolute $ Opportunity Analysis By End-use, 2024-2031

9. Global Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness Analysis By Region

10. North America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 10.2.1. By Country
      • 10.2.1.1. U.S.
      • 10.2.1.2. Canada
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End-use
  • 10.3. Market Attractiveness Analysis
    • 10.3.1. By Country
    • 10.3.2. By Product Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End-use
  • 10.4. Key Takeaways

11. Latin America Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 11.2.1. By Country
      • 11.2.1.1. Brazil
      • 11.2.1.2. Mexico
      • 11.2.1.3. Rest of Latin America
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End-use
  • 11.3. Market Attractiveness Analysis
    • 11.3.1. By Country
    • 11.3.2. By Product Type
    • 11.3.3. By Technology
    • 11.3.4. By Application
    • 11.3.5. By End-use
  • 11.4. Key Takeaways

12. Europe Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 12.2.1. By Country
      • 12.2.1.1. Germany
      • 12.2.1.2. U.K.
      • 12.2.1.3. France
      • 12.2.1.4. Spain
      • 12.2.1.5. Italy
      • 12.2.1.6. Russia
      • 12.2.1.7. Rest of Europe
    • 12.2.2. By Product Type
    • 12.2.3. By Technology
    • 12.2.4. By Application
    • 12.2.5. By End-use
  • 12.3. Market Attractiveness Analysis
    • 12.3.1. By Country
    • 12.3.2. By Product Type
    • 12.3.3. By Technology
    • 12.3.4. By Application
    • 12.3.5. By End-use
  • 12.4. Key Takeaways

13. Asia Pacific Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 13.2.1. By Country
      • 13.2.1.1. China
      • 13.2.1.2. Japan
      • 13.2.1.3. India
      • 13.2.1.4. South Korea
      • 13.2.1.5. Australia
      • 13.2.1.6. Rest of APAC
    • 13.2.2. By Product Type
    • 13.2.3. By Technology
    • 13.2.4. By Application
    • 13.2.5. By End-use
  • 13.3. Market Attractiveness Analysis
    • 13.3.1. By Country
    • 13.3.2. By Product Type
    • 13.3.3. By Technology
    • 13.3.4. By Application
    • 13.3.5. By End-use
  • 13.4. Key Takeaways

14. Middle East and Africa Infectious Disease In-vitro Diagnostics Market Analysis 2019-2023 and Forecast 2024-2031, By Country

  • 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
    • 14.2.1. By Country
      • 14.2.1.1. South Africa
      • 14.2.1.2. Saudi Arabia
      • 14.2.1.3. UAE
      • 14.2.1.4. Israel
      • 14.2.1.5. Rest of MEA
    • 14.2.2. By Product Type
    • 14.2.3. By Technology
    • 14.2.4. By Application
    • 14.2.5. By End-use
  • 14.3. Market Attractiveness Analysis
    • 14.3.1. By Country
    • 14.3.2. By Product Type
    • 14.3.3. By Technology
    • 14.3.4. By Application
    • 14.3.5. By End-use
  • 14.4. Key Takeaways

15. Key Countries Infectious Disease In-vitro Diagnostics Market Analysis

  • 15.1. U.S.
    • 15.1.1. Pricing Analysis
    • 15.1.2. Market Share Analysis, 2024
      • 15.1.2.1. By Product Type
      • 15.1.2.2. By Technology
      • 15.1.2.3. By Application
      • 15.1.2.4. By End-use
  • 15.2. Canada
    • 15.2.1. Pricing Analysis
    • 15.2.2. Market Share Analysis, 2024
      • 15.2.2.1. By Product Type
      • 15.2.2.2. By Technology
      • 15.2.2.3. By Application
      • 15.2.2.4. By End-use
  • 15.3. Brazil
    • 15.3.1. Pricing Analysis
    • 15.3.2. Market Share Analysis, 2024
      • 15.3.2.1. By Product Type
      • 15.3.2.2. By Technology
      • 15.3.2.3. By Application
      • 15.3.2.4. By End-use
  • 15.4. Mexico
    • 15.4.1. Pricing Analysis
    • 15.4.2. Market Share Analysis, 2024
      • 15.4.2.1. By Product Type
      • 15.4.2.2. By Technology
      • 15.4.2.3. By Application
      • 15.4.2.4. By End-use
  • 15.5. Germany
    • 15.5.1. Pricing Analysis
    • 15.5.2. Market Share Analysis, 2024
      • 15.5.2.1. By Product Type
      • 15.5.2.2. By Technology
      • 15.5.2.3. By Application
      • 15.5.2.4. By End-use
  • 15.6. U.K.
    • 15.6.1. Pricing Analysis
    • 15.6.2. Market Share Analysis, 2024
      • 15.6.2.1. By Product Type
      • 15.6.2.2. By Technology
      • 15.6.2.3. By Application
      • 15.6.2.4. By End-use
  • 15.7. France
    • 15.7.1. Pricing Analysis
    • 15.7.2. Market Share Analysis, 2024
      • 15.7.2.1. By Product Type
      • 15.7.2.2. By Technology
      • 15.7.2.3. By Application
      • 15.7.2.4. By End-use
  • 15.8. Spain
    • 15.8.1. Pricing Analysis
    • 15.8.2. Market Share Analysis, 2024
      • 15.8.2.1. By Product Type
      • 15.8.2.2. By Technology
      • 15.8.2.3. By Application
      • 15.8.2.4. By End-use
  • 15.9. Italy
    • 15.9.1. Pricing Analysis
    • 15.9.2. Market Share Analysis, 2024
      • 15.9.2.1. By Product Type
      • 15.9.2.2. By Technology
      • 15.9.2.3. By Application
      • 15.9.2.4. By End-use
  • 15.10. Russia
    • 15.10.1. Pricing Analysis
    • 15.10.2. Market Share Analysis, 2024
      • 15.10.2.1. By Product Type
      • 15.10.2.2. By Technology
      • 15.10.2.3. By Application
      • 15.10.2.4. By End-use
  • 15.11. China
    • 15.11.1. Pricing Analysis
    • 15.11.2. Market Share Analysis, 2024
      • 15.11.2.1. By Product Type
      • 15.11.2.2. By Technology
      • 15.11.2.3. By Application
      • 15.11.2.4. By End-use
  • 15.12. Japan
    • 15.12.1. Pricing Analysis
    • 15.12.2. Market Share Analysis, 2024
      • 15.12.2.1. By Product Type
      • 15.12.2.2. By Technology
      • 15.12.2.3. By Application
      • 15.12.2.4. By End-use
  • 15.13. India
    • 15.13.1. Pricing Analysis
    • 15.13.2. Market Share Analysis, 2024
      • 15.13.2.1. By Product Type
      • 15.13.2.2. By Technology
      • 15.13.2.3. By Application
      • 15.13.2.4. By End-use
  • 15.14. South Korea
    • 15.14.1. Pricing Analysis
    • 15.14.2. Market Share Analysis, 2024
      • 15.14.2.1. By Product Type
      • 15.14.2.2. By Technology
      • 15.14.2.3. By Application
      • 15.14.2.4. By End-use
  • 15.15. Australia
    • 15.15.1. Pricing Analysis
    • 15.15.2. Market Share Analysis, 2024
      • 15.15.2.1. By Product Type
      • 15.15.2.2. By Technology
      • 15.15.2.3. By Application
      • 15.15.2.4. By End-use
  • 15.16. South Africa
    • 15.16.1. Pricing Analysis
    • 15.16.2. Market Share Analysis, 2024
      • 15.16.2.1. By Product Type
      • 15.16.2.2. By Technology
      • 15.16.2.3. By Application
      • 15.16.2.4. By End-use
  • 15.17. Saudi Arabia
    • 15.17.1. Pricing Analysis
    • 15.17.2. Market Share Analysis, 2024
      • 15.17.2.1. By Product Type
      • 15.17.2.2. By Technology
      • 15.17.2.3. By Application
      • 15.17.2.4. By End-use
  • 15.18. UAE
    • 15.18.1. Pricing Analysis
    • 15.18.2. Market Share Analysis, 2024
      • 15.18.2.1. By Product Type
      • 15.18.2.2. By Technology
      • 15.18.2.3. By Application
      • 15.18.2.4. By End-use
  • 15.19. Israel
    • 15.19.1. Pricing Analysis
    • 15.19.2. Market Share Analysis, 2024
      • 15.19.2.1. By Product Type
      • 15.19.2.2. By Technology
      • 15.19.2.3. By Application
      • 15.19.2.4. By End-use

16. Market Structure Analysis

  • 16.1. Competition Dashboard
  • 16.2. Competition Benchmarking
  • 16.3. Market Share Analysis of Top Players
    • 16.3.1. By Regional
    • 16.3.2. By Product Type
    • 16.3.3. By Technology
    • 16.3.4. By Application
    • 16.3.5. By End-use

17. Competition Analysis

  • 17.1. Competition Deep Dive
    • 17.1.1. Becton, Dickinson and Company
      • 17.1.1.1. Overview
      • 17.1.1.2. Product Portfolio
      • 17.1.1.3. Profitability by Market Segments
      • 17.1.1.4. Sales Footprint
      • 17.1.1.5. Strategy Overview
        • 17.1.1.5.1. Marketing Strategy
    • 17.1.2. bioMerieux SA
      • 17.1.2.1. Overview
      • 17.1.2.2. Product Portfolio
      • 17.1.2.3. Profitability by Market Segments
      • 17.1.2.4. Sales Footprint
      • 17.1.2.5. Strategy Overview
        • 17.1.2.5.1. Marketing Strategy
    • 17.1.3. Abbott
      • 17.1.3.1. Overview
      • 17.1.3.2. Product Portfolio
      • 17.1.3.3. Profitability by Market Segments
      • 17.1.3.4. Sales Footprint
      • 17.1.3.5. Strategy Overview
        • 17.1.3.5.1. Marketing Strategy
    • 17.1.4. Quidel Corporation
      • 17.1.4.1. Overview
      • 17.1.4.2. Product Portfolio
      • 17.1.4.3. Profitability by Market Segments
      • 17.1.4.4. Sales Footprint
      • 17.1.4.5. Strategy Overview
        • 17.1.4.5.1. Marketing Strategy
    • 17.1.5. OraSure Technologies, Inc
      • 17.1.5.1. Overview
      • 17.1.5.2. Product Portfolio
      • 17.1.5.3. Profitability by Market Segments
      • 17.1.5.4. Sales Footprint
      • 17.1.5.5. Strategy Overview
        • 17.1.5.5.1. Marketing Strategy
    • 17.1.6. Hologic Inc.
      • 17.1.6.1. Overview
      • 17.1.6.2. Product Portfolio
      • 17.1.6.3. Profitability by Market Segments
      • 17.1.6.4. Sales Footprint
      • 17.1.6.5. Strategy Overview
        • 17.1.6.5.1. Marketing Strategy
    • 17.1.7. Cepheid
      • 17.1.7.1. Overview
      • 17.1.7.2. Product Portfolio
      • 17.1.7.3. Profitability by Market Segments
      • 17.1.7.4. Sales Footprint
      • 17.1.7.5. Strategy Overview
        • 17.1.7.5.1. Marketing Strategy
    • 17.1.8. Qiagen
      • 17.1.8.1. Overview
      • 17.1.8.2. Product Portfolio
      • 17.1.8.3. Profitability by Market Segments
      • 17.1.8.4. Sales Footprint
      • 17.1.8.5. Strategy Overview
        • 17.1.8.5.1. Marketing Strategy
    • 17.1.9. F. Hoffmann-La Roche Ltd.
      • 17.1.9.1. Overview
      • 17.1.9.2. Product Portfolio
      • 17.1.9.3. Profitability by Market Segments
      • 17.1.9.4. Sales Footprint
      • 17.1.9.5. Strategy Overview
        • 17.1.9.5.1. Marketing Strategy
    • 17.1.10. Siemens Healthcare GmbH
      • 17.1.10.1. Overview
      • 17.1.10.2. Product Portfolio
      • 17.1.10.3. Profitability by Market Segments
      • 17.1.10.4. Sales Footprint
      • 17.1.10.5. Strategy Overview
        • 17.1.10.5.1. Marketing Strategy
    • 17.1.11. Bio-Rad Laboratories, Inc.
      • 17.1.11.1. Overview
      • 17.1.11.2. Product Portfolio
      • 17.1.11.3. Profitability by Market Segments
      • 17.1.11.4. Sales Footprint
      • 17.1.11.5. Strategy Overview
        • 17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology